December - 2020
| Previous Next | Showing Journal 4 of 10 |
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19A Kalil, T Patterson, A Mehta et al for the New Eng J Med, 2020, December 11 This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register |
December |
Previous Comments
No Comments yet.
Comment
The ACTT-2 trial, a double blinded RCT tested whether the addition of baricitinib to remdesivir, improved time to recovery in adult patients hospitalised with COVID-19
Baricitinib is a Janus kinase inhibitor, orally administered, and;